A phase I trial is exploring the combination of cemiplimab with BNT116 as compared to cemiplimab alone for the first-line treatment of advanced NSCLC and PD-L1 ≥ 50% (NCT05557591). The gene discussed is CD274; the disease is non-small cell lung carcinoma.